Student experience on clinical placement is not well captured with traditional program evaluation tools. This study aims to complete a qualitative analysis of the reflective clinical journals completed during professional placement by radiation therapy (RT) students in order to uncover the issues that affect students on placement and how these change as the student's progress through the program.

A qualitative descriptive analysis (QDA) was undertaken on the descriptive content of student journals completed by 97 students over 3 consecutive years while undertaking professional placement in Radiation Oncology Treatment Centres within Australia. Two coders used a QDA sourcebook specifically designed for the research to independently analyse the descriptive content of the reflective journals for four main categories and 18 subcategories.

The result revealed a statistically significant increased tendency to discuss clinical environment and a decreased tendency to discuss the patient, 92·9–12·5% (coder 1) and 85·7–18·8% (coder 2), as they progressed through the program.

The results of this study showed some similarities with studies completed in other health professions; however, the breadth of issues explored within the content of these RT student journals demonstrates the true diversity of the RT student experience on professional placement.

At Queensland University of Technology, student radiation therapists receive regular feedback from clinical staff relating to clinical interpersonal skills. Although this is of great value, there is anecdotal evidence that students communicate differently with patients when under observation.

The aim of this pilot was to counter this perceived observer effect by allowing patients to provide students with additional feedback.

Radiotherapy patients from two departments were provided with anonymous feedback forms relating to aspects of student interpersonal skills. Clinical assessors, mentors and students were also provided with feedback forms, including questions about the role of patient feedback. Patient perceptions of student performance were correlated with staff feedback and assessment scores.

Results indicated that the feedback was valued by both students and patients. Students reported that the additional dimension focused them on communication, set goals for development and increased motivation. These changes derived from both feedback and study participation, suggesting that the questionnaires could be a useful teaching tool. Patients scored more generously than mentors, although there was agreement in relative grading.

The anonymous questionnaire is a convenient and valuable method of gathering patient feedback on students. Future iterations will determine the optimum timing for this method of feedback.

To calculate and compare planning target volume (PTV) margins for an offline 3 mm tolerance, daily bony anatomy verification, tattoo alignment and online prostate marker matching with those currently used at our institution.

Seventy patients had offline bony anatomy megavoltage verification. 23 different patients underwent fiducial marker matching using daily online kilovoltage verification. Systematic and random errors were measured in the right–left (RL), superior–inferior (SI) and anterior–posterior (AP) directions. Geometric uncertainties from literature were used to help calculate the margins.

PTV margins (mm) were 7 RL, 12 SI and AP (3 mm tolerance offline bony), 6 RL, 11 SI and AP (daily online bony), 8 RL, 12 SI and AP (tattoo alignment) and 5 RL, 8 SI and 6 AP (online daily prostate marker correction).

Our current margins for conformal radiotherapy patients are too small for phase 2 in the SI and AP directions. Implementing online daily bony anatomy matching would not reduce the PTV margin significantly. Online daily marker correction showed current PTV71 Gy margins as excessive by (mm) 5 RL, 2 SI and 4 anterior.

Current guidelines for image-guided cervical cancer brachytherapy planning recommend both computed tomography (CT) and magnetic resonance imaging (MRI) for adequate visualisation of the applicator and soft tissues, respectively. MRI-only planning would be ideal as it would save time within the patient pathway and avoid the concomitant CT exposures. However, applicator visualisation on MRI is usually achieved using fluid-filled fiducial marker tubes, which can be awkward to use and suffer from unwanted air bubble artefacts. Therefore, a new fiducial-free imaging technique was developed.

A dual echo time (TE) turbo spin echo sequence was used, at 1·5 T, to provide both T2-weighted images (100 ms TE) for tissue visualisation and strongly proton density-weighted images (17 ms TE) for improved applicator visualisation. In-house software was used to automatically segment the applicator in the short TE images (using Otsu's method) and transfer the information to the long TE images to provide a single fused dataset.

The method was evaluated successfully using titanium applicators in three patient cases and using a plastic applicator in a tissue-equivalent gel phantom.

The dual-echo technique provides a simple and efficient method for improving the visualisation of brachytherapy applicators in cervical cancer MRI images without the need for marker tubes.

Geometric uncertainties limit the accuracy of three-dimensional conformal radiotherapy treatments. This study aims to evaluate typical random and systematic set-up errors and analyse the impact of no action level (NAL) correction protocol on systematic set-up errors and clinical target volume (CTV)–planning target volume (PTV) margins.

A total 668 pairs of orthogonal electronic portal images were compared with digitally reconstructed radiographs from computed tomography planning scans for 100 patients consecutively treated during 2011. Patients were divided into groups depending on the treated anatomical region. Patient-specific and population random and systematic set-up errors were calculated. Impact of application of NAL correction protocol on systematic set-up errors and CTV–PTV expansions were evaluated.

Population set-up errors resulted from about 1 mm in head and neck to 2–3 mm in prostate, rectum, lung, breast and gynaecological districts. Patient-specific systematic set-up errors were higher for breast and gynaecological districts and application of NAL correction protocol gave significant reductions, even higher than 30%. Calculated CTV–PTV margins ranged from 10 mm on left–right direction for prostate to 20 mm on superior–inferior direction for lung.

Set-up errors resulted reasonably controlled and application of NAL correction protocol could further improve the level of accuracy. However, the NAL application alone did not seem to add any substantial benefit on CTV–PTV total margins without the adoption of corrective strategies to reduce other important uncertainties limiting accuracy of three-dimensional conformal radiotherapy.

The main aim was to use pre-calculated correction factors and calibration factors for measurement of accuracy of dose delivery before implementation of such in vivo dosimetry on real patients visiting for first radiation treatment. These factors were verified by generating the most common treatment plans on human phantom except for breast and colon using cobalt-60 unit.

Six treatment plans were generated, i.e. nasopharynx, bladder, prostate, brain, larynx and lung of human phantom, total 18 fields were planned keeping in view the correction factors which are to be verified. MULTIDATA Decision Support System 2.5, Shimadzu simulator, Isorad diode-n type, electrometer patient dose monitor and ATOM Adult male human phantom were used.

For 18 fields, the dose delivery was accurate in the range 0·29–6·74%. The deviation between measured and expected doses to nasopharynx, lung, bladder, prostate, brain and larynx cases of human phantom ranged from 1·44–3·89%, 0·29–0·54%, 0·44–6·18%, 0·54–5·16%, 0·33–4·90%, 5·58–6·74%, respectively. In 30 palliative patient cases, the first radiation treatment was also monitored. The accuracy of dosimety ranged from 1·05% to 5·35%. This study is helpful to identify areas of improvement in treatment of patients like quality control/quality assurance (QA) of treatment planning system, beam data modifications, machine repair maintenance, QA audit in radiotherapy.

We propose to use the PTV dose–volume factor (PDVF) to evaluate treatment plans of prostate volumetric modulated arc therapy (VMAT) and intensity modulated radiotherapy (IMRT).

PDVF was used to compare the variation of planning target volume (PTV) coverage between VMAT and IMRT because of weight loss of patient.

VMAT and IMRT plans of five patients (prostate volume = 32–86·5 cm3) using the 6 MV photon beams were created with the external contour reduced by depths of 0·5–2 cm to reflect the weight loss. Moreover, integral doses (volume integral of the patient dose) and prostate tumour control probability (TCP) were calculated.

We found that reduced depth resulted in PDVF decreasing 0·03 ± 4·7 × 10−4 (VMAT) and 0·04 ± 9·7 × 10−3 (IMRT) per cm for patients. The decrease of PDVF or degradation of PTV coverage was found more significant in IMRT plans than VMAT with patient size reduction. The integral dose did not change significantly between VMAT and IMRT, while the prostate TCP increased with an increase of reduced depth.

We concluded that PDVF can be successfully used to evaluate the variation of PTV coverage because of weight loss of patient in prostate VMAT and IMRT. Degradation of PTV coverage in prostate VMAT is less significant than IMRT regarding patient size reduction.

To quantify the amount of inter-fractional pitch for rectal carcinoma patients, to investigate the dosimetric impact of pitch on the target volume and critical structures and to determine a tolerance where no pitch correction is required.

Daily pre-treatment images of rectal carcinoma patients were analysed to determine the residual pitch compared with the computed tomography (CT) planning scan. The dosimetric impact of pelvic rotation was modelled. The dose coverage of the clinical target volume (CTV) and small bowel were evaluated using dose–volume histograms.

Pre-treatment images had a mean of 0·27° and standard deviation was 2·23°. The volume of CTV receiving 95% of the prescription dose altered by 0·1% when up to ±10° of pitch was simulated.

No clinically significant change in CTV coverage was found (when ±10° of pitch was simulated). A tolerance of ±10° of pitch has been implemented for rectal carcinoma patients treated with three-dimensional conformal radiotherapy in our institution, when daily pre-treatment imaging with a zero action threshold for translational shifts is used.

This study used receiver operating characteristic curve (ROC) to analyse surveillance, epidemiology and end results (SEER) adenoid cystic carcinoma data to identify predictive models and potential disparity in outcome.

For the risk modelling, each factor was fitted by a generalised linear model to predict the cause-specific survival. The area under the ROC was computed. Similar strata were combined to construct the most parsimonious models. A random sampling algorithm was used to estimate the modelling errors. Risk of adenoid cystic carcinoma death was computed for the predictors for comparison.

There were 5,947 patients diagnosed from 1973 to 2009 included in this study. The mean follow-up time (SD) was 93·8 (90·6) months. Three out of five patients were women. The mean (SD) age was 58·55 (16·01) years. SEER stage was the most predictive factor of outcome (ROC area of 0·68). Sex, radiotherapy and surgery had ROC areas of about 0·57. None of the socio-economic disparities was found for treatment outcome. Radiotherapy was underused in localised and regional stages when the intent was curative, especially in older patients.

Anatomical staging was predictive and useful in treatment selection. Understaging and underuse of radiotherapy may have contributed to poor outcomes.

We studied symptomatic radiation pneumonitis (RP) and changes in pulmonary function tests (PFTs) after loco-regional radiotherapy (LRRT) with V20 lung constraints in breast cancer (BC).

Sixty-four women underwent PFTs before and 5 months after 3D planned LRRT for BC. The incidentally irradiated ipsilateral lung V20 was minimised to <30%. Patients were monitored for symptoms of RP 1, 4 and 7 months after radiotherapy (RT) and data on covariates were collected prospectively. The outcome was compared with previous treatment series.

Pneumonitis was less frequent with the applied constraint, that is, four mild and one moderate case, than in our previous report (p < 0·001). In multivariate analyses, neither dosimetric data nor covariates appeared to influence mean changes in vital capacity [−0·11L, standard error of the mean (SEM) 0·03] or diffusing capacity of the lung for carbon monoxide (DLCO) (−0·20 mmol/kPa/min, SEM 0·01), except for pre-RT chemotherapy, which diminished the change in DLCO 5 months post-RT.

The used constraint and 3D planning lowered the rate of RP and short-term changes in PFTs compared with our previous treatment series. Pre-RT chemotherapy affects DLCO baseline levels. Rates of side effects should be continuously studied when new target definitions or therapies are introduced in LRRT of BC.

Oral mucositis is common for patients undergoing chemoradiotherapy for squamous cell carcinoma of the head and neck (SCCHN). Despite the significant detrimental sequelae associated, there is no consensus on the optimum mouth care regimen. This prospective audit aims to record mucositis and dysphagia toxicity and the level of analgesia prescribed when recent products: MuGard™, Caphosol® and Episil® are compared with our standard departmental mouth care regimen.

Patients undergoing concurrent chemoradiotherapy for locally advanced SCCHN at University Hospital Birmingham, UK were prospectively audited weekly for 8 consecutive weeks starting from week 1 of chemoradiotherapy from June 2009 until January 2011. Patients received either standard oral care regimen of aspirin, glycerin and sucralfate, or, MuGard™, Caphosol® or Episil®. Grade of mucositis, dysphagia and analgesia score were prospectively recorded using the common toxicity criteria v3·0.

One hundred and four patients were included. There was no difference in the grade and duration of mucositis (p = 0·82), dysphagia (p = 0·99) or analgesia score (p = 0·61) for either MuGard™, Caphosol® or Episil® compared with standard oral care.

There is no evidence from this audit that Mugard™, Caphosol® or Episil® improves mucositis and dysphagia toxicity or the level of analgesia prescribed compared with our standard departmental mouth care regimen. Randomised trials comparing these approaches are required to detect any meaningful clinical benefit.

Patients with cancer undergoing radiotherapy often develop diarrhoea, causing distress and hindering treatment. As probiotics have favourable effects on the gut flora, they are potentially good candidates in the prevention of radiotherapy-induced diarrhoea (RID).

The outcome of interest of this systematic review was the efficacy of probiotics in preventing RID.

Medline and Embase databases were systematically searched. Four randomised controlled trials (RCTs) were finally selected.

Three RCTs showed beneficial results, which were statistically significant. One RCT showed non-beneficial results, which were not statistically significant. The quality of the studies was mixed, and serious limitations were found.

While the indications are towards a benefit of the use of probiotics in preventing RID, more robust evidence is required in the form of well-designed RCTs.

Metastasis to the thyroid gland is a rare event.

We describe an unusual case of a 38-year-old woman with a history of small-cell lung cancer (SCLC), presenting with a new nodule in the thyroid gland, found to be metastatic SCLC, without evidence of widespread dissemination.

A new thyroid nodule should be carefully evaluated for metastasis in a patient with a history of prior malignancy.

Varian RapidArc is a volumetric modulated arc therapy (VMAT) that obtains a conformal dose around the desired structure by employing variable gantry speed, dose rate and dynamic multileaf collimator (DMLC) speed as the gantry rotates about machine isocenter. This study is meant to build upon previous research by Ling et al. by completing the tests with an in vivo dosimetric device attached to the linac gantry and a 2D ionisation chamber array with an isocentric gantry mount.

Two PTW detectors, seven29 array with gantry mount and DAVID, were attached to the linear accelerator gantry, allowing each device to remain perpendicular to the beam at all gantry angles. Three tests for RapidArc evaluation were performed on these devices including: dose rate and gantry speed variation, DMLC speed and dose rate variation and DMLC position accuracy. The reproducibility of the arc data was also reported.

A picket fence plan varying dose rates (111 to 600 MU/minute) and gantry speeds (5·5 to 4·3°/second) was delivered consisting of seven sections of different combinations. These measurements were compared with static gantry, open field measurements and found to be within 2·39% for the DAVID device and 0·84% for the seven29. A four-section picket fence of varying DMLC speeds (0·46, 0·92, 1·84 and 2·76 cm/second) was similarly evaluated and found to be within 1·99% and 3·66% for the DAVID and seven29, respectively. For DMLC position accuracy, a picket fence arc plan was compared with a static picket fence and found to agree within 0.38% and 2.91%. Reproducibility for these three RapidArc plans was found to be within 0·30% and 2·70% for the DAVID and seven29.

The DAVID and seven29 detectors were able to perform the RapidArc quality assurance tests efficiently and accurately and the results were reproducible. Periodic verification of DMLC movement, dose rate variation and gantry speed variation relating to RapidArc delivery can be completed in a timelier manner using this equipment.